Login to Your Account

Clinic Roundup

Thursday, July 26, 2012
• Bio-Path Holdings Inc., of Houston, said it started enrolling patients in the fourth dosage cohort for its Phase I trial of lead candidate BP-100.1.01 (liposomal Grb-1), which is being evaluated as a systemic treatment for blood cancers, including acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic leukemia and myelodysplastic syndrome.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription